News
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
10h
Zacks.com on MSNNovavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...
Brad Smith outlines the top stories on Wall Street as part of Yahoo Finance's Market Minute. Vertiv Holdings (VRT) stock is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results